Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Kinnate Biopharma Inc. is a biotechnology firm focused on developing targeted therapies for cancer, particularly in the area of precision medicine. Its lead product candidate, KIN-2787, is currently in clinical trials for treating solid tumors, which positions the company within the competitive landscape of oncology-focused biotech firms.
Kinnate Biopharma primarily aims to generate revenue through the commercialization of its oncology therapies, particularly KIN-2787, once it receives regulatory approval. The company also seeks to establish partnerships with larger pharmaceutical firms to leverage their distribution capabilities, although it currently lacks revenue generation.
Progress in clinical trials for KIN-2787, particularly Phase 2 results
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from the FDA or EMA
Market sentiment towards oncology biotech sector
Regulatory changes that could affect drug approval processes
Technological disruption in cancer treatment methodologies
Emergence of new therapies from competitors that could outperform KIN-2787
Potential for larger pharmaceutical companies to dominate the oncology market
High cash burn rate with negative operating cash flow of $-0.1B
Dependence on future funding to sustain operations
low - The demand for cancer therapies is relatively inelastic, making the company less sensitive to economic cycles.
Moderate - Higher interest rates could increase the cost of capital for funding clinical trials, impacting future growth prospects.
minimal - The company has low debt levels, with a Debt/Equity ratio of 0.02, indicating limited reliance on credit.
growth - Investors looking for high-risk, high-reward opportunities in biotech.
high - The stock has shown significant volatility, with a 6-month return of 108.7%.
